Background: In the present cross-sectional study we investigated whether familial combined hyperlipidemia (FCH) is associated with an increased arterial wall stiffness, and whether measures of arterial wall stiffness in FCH family members could contribute to cardiovascular risk stratification.
F
amilial combined hyperlipidemia (FCH) is the most common form of heritable lipid disorder, with a prevalence of up to 5% in the general population, and 10% to 20% in survivors of myocardial infarction. 1, 2 It is characterized by several phenotypes, including elevated plasma levels of total cholesterol (TC), triglycerides (TG), or apolipoprotein B (ApoB). Other characteristics of FCH are decreased plasma levels of HDL-cholesterol, the presence of small dense LDL particles, a decreased insulin sensitivity, and the presence of visceral obesity. [3] [4] [5] All of these clinical and biochemical characteristics may contribute to the observed increased risk of cardiovascular disease (CVD) in subjects with FCH. 6 However, FCH is a heterogeneous disorder with a highly variable phenotypic expression between subjects. Phenotypic expression varies even within subjects over time. 7 Because of the variability in expression, quantification of a subset of cardiovascular risk factors (as usually happens in clinical practice) might result in suboptimal prediction of CVD risk in an individual. Another major problem in clinical medicine is that at every level of traditional risk factor exposure, there is a large interindividual variation in the amount of atherosclerosis and the development of CVD. Therefore, an indicator that directly reflects the presence of atherosclerosis in the vessel wall (and thereby the overall effect of all potential risk factors) is expected to yield a better risk prediction. Pulse wave velocity (PWV) and augmentation index (AIx) are attractive candidate representatives of such an overall effect. The AIx is a marker of pressure wave reflection, whereas PWV is a surrogate measure of arterial wall stiffness. An increased arterial wall stiffness has been associated with both the severity of coronary artery disease 8 and carotid artery disease. 9 Furthermore, increased arterial wall stiffness has been associated with coronary risk scores in healthy subjects 10 and, more important, it has been shown to predict future morbidity and mortality in hypertensive and diabetic populations. 11, 12 Very recently, it was shown that PWV is an independent predictor of coronary heart disease and stroke in apparently healthy subjects. 13, 14 In the present cross-sectional study we investigated whether PWV and AIx, as determined with applanation tonometry, are disturbed in patients with FCH compared to their normolipidemic relatives. Furthermore, we investigated whether PWV and AIx can be used to stratify CVD risk in FCH family members with additional power beyond traditional risk factor screening.
Methods

Study Population
The study population consisted of 32 families, comprising 343 subjects. These families were ascertained through probands exhibiting a combined hyperlipidemia, as described previously. 7, 15, 16 The FCH diagnosis was based on absolute apoB levels in combination with plasma TG and TC levels, adjusted for age and gender, using our recently published nomogram. 16 In total 98 subjects were diagnosed as FCH and 230 as unaffected relatives. Cardiovascular disease was defined by stroke, myocardial infarction (MI), angina pectoris (AP), peripheral vascular disease, or revascularization procedure. When the presence of CVD was suspected by the clinical investigator, further details were sought from the patients' general practitioner or from any relevant hospital records. In total, 43 subjects were diagnosed with CVD, including 4 subjects with stroke, 12 subjects with previous MI, 14 subjects with AP, 6 subjects with peripheral vascular disease, and 12 subjects with a revascularization procedure. Twenty-six percent (n ϭ 11) of these subjects were diagnosed with CVD based on the presence of two or more manifestations of CVD. All individuals with secondary causes of hyperlipidemia (diabetes, renal or hepatic insufficiency, hypothyroidism, or medication), with the apo E2/E2 genotype, or tendon xanthomas were excluded. The Medical Ethics Committee of the Radboud UMC approved the study protocol, and all participants provided written informed consent.
Clinical Measurements
All subjects filled out a lifestyle questionnaire about their previous medical history, and their medication use, with special attention to the use of vasoactive medication, defined as the use of one or more of the following drug classes on a regular, daily basis: angiotensinconverting enzyme (ACE) inhibitors, angiotensin II inhibitors, nitrates, calcium-channel blockers, diuretics, or ␤-blockers.
Waist circumference was measured at the level of the umbilicus. Systolic and diastolic blood pressures (BP) were measured at the brachial artery using an oscillometric sphygmomanometer (Critikon model no.1846; Critikon Inc., Tampa, FL), and mean arterial pressure (MAP) was calculated as: Diastolic BP ϩ 0.33 (Systolic BP Ϫ Diastolic BP).
Biochemical Analyses
Venous blood was drawn after an overnight fast, and plasma TC and TG concentrations were determined using commercially available enzymatic reagents (Hitachi 747; Roche, Almere, The Netherlands). Very low density lipoprotein (VLDL)-cholesterol was isolated from whole plasma by ultracentrifugation at density (d) ϭ 1.006 g/mL for 16 h at 36,000 rpm in a fixed angle rotor. The HDLcholesterol was determined by the polyethylene glycol 6000 method. 17 The LDL-cholesterol was calculated by subtraction of VLDL-cholesterol and HDL-cholesterol from plasma TC. Total plasma apoB concentration was determined by immunonephelometry. 18 Both high-sensitive C-reactive protein (hsCRP) (Dako, Glastrup, Denmark) and plasma oxidized LDL (oxLDL) (Mercodia, Uppsala, Sweden) were determined by ELISA. Plasma glucose was determined by a commercially available glucose oxidation method (GOD-PAP, Hitachi 747; Roche Molecular Biochemicals, Indianapolis, IN). Serum insulin concentration was assessed by means of an in-house radioimmunoassay (interassay coefficient of variation: 10.3%). 19 Insulin resistance was assessed by the Homeostasis model assessment (HOMA).
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Augmentation Index and Pulse Wave Velocity Measurements
All measurements were taken in the supine position in a temperature-controlled room (22°C) after a brief period (at least 5 min) of rest. 21 Peripheral arterial pressure waveforms were recorded by applanation tonometry at the radial artery, using the commercially available Sphygmocor system version 7.1 (Atcor Medical, Sydney, Australia). The corresponding central waveform was then derived by applying a validated integral transfer function on the average peripheral waveform, 22, 23 and subjected to further analysis to determine AIx, defined as the difference between the first and second peak of the central arterial waveform, expressed as a percentage of the pulse pressure. Because AIx is influenced by heart rate, 24 an index normalized for heart rate of 75 beats per minute (AIx@75) was used. To determine PWV, pulse waveforms were recorded at two sites sequentially (right carotid artery and left femoral artery), and wave transit time was calculated using the R-wave of a simultaneously recorded electrocardiogram (ECG) as a reference frame. Surface distance between the two recording sites was measured parallel to the plane of the examination table, and the distance between the carotid artery site and the manubrium was subtracted from the total distance, allowing PWV to be calculated. All measurements had to meet the criteria of optimal quality as defined by the manufacturer. According to these standards, AIx was acquired in 306 subjects (93%) and PWV in 311 subjects (94%). The reproducibility of the AIX and PWV measurements was good, as has been reported in a previous study. 25 The mean difference Ϯ repeatability coefficient for repeated measurements by the same observer was 0.68% Ϯ 4.87% for AIx and 0.19 Ϯ 0.52 m/sec for PWV.
Statistics
Variables with a skewed distribution were logarithmically transformed before analysis. Comparisons between FCH patients and their unaffected relatives for PWV and AIx were performed by general linear model (GLM) with age, gender, MAP, "vasoactive medication use," and body height (AIx only) as covariates, and family number as a random factor. The MAP was used as a covariate (and not systolic or diastolic BP), as it had the strongest correlation with PWV in multivariate analysis with adjustment for age and gender (standardized beta (St␤) resp. 0.34, 0.33, and 0.28). Univariate logistic regression was used to evaluate the prognostic ability of the variables separately to discriminate between subjects affected by CVD and their unaffected relatives. Because most variables were expected to be nonlinearly related in the logistic model, reasonable cutoff values for these variables to discriminate between affected subjects and their unaffected relatives were constructed. At this point, the condition of equal "costs" of misclassification of cases and noncases was used. Subsequently, multivariate logistic regression analysis with backward selection procedures was used to determine which age-and gender-adjusted clinical and biochemical variables contributed independently to the prediction of CVD. Next, with the multivariable prognostic model, a boundary value of probability to be affected by CVD was derived for the most predictive combination of age-and gender-adjusted clinical and biochemical variables as derived from multivariate logistic regression analysis, again under the condition of equal costs of misclassification. Finally, the prognostic ability of this boundary value was compared to the optimal cutoff points for age-and gender-adjusted PWV and AIx to predict CVD, using receiver-operating curve characteristics. A P value Ͻ .05 was considered statistically significant. Statistical analyses were done with the SPSS 12.0.1 for Windows statistical package (SPSS Inc., Chicago IL) and STATA 8.0 software. Table 1 shows the clinical and biochemical characteristics for FCH patients and their unaffected relatives. Patients with FCH were on average 7 years older than their unaffected relatives and used significantly more often vasoactive medication. In addition, FCH patients had a greater waist circumference, were more insulin resistant (as reflected by a higher HOMA index), had a less favorable lipid profile, and a higher plasma level of hsCRP compared to their unaffected relatives. Although systolic and diastolic BP and MAP tended to be higher in FCH patients, the differences with their unaffected relatives did not reach statistical significance. The number of subjects affected by any past or present CVD was significantly higher among FCH patients. As expected, FCH patients with a history of prevalent CVD exhibited a more unfavorable risk factor profile than FCH patients without CVD, although differences did not reach statistical significance for most parameters, most probably due to the relatively small number of subjects with FCH and CVD (n ϭ 21; data not shown).
Results
Clinical and Biochemical Characteristics of FCH Families
Pulse Wave Analysis in FCH Families
A general linear model with adjustment for age, gender, MAP, use of vasoactive medication, and family number revealed that the PWV of patients with FCH was significantly higher compared to the PWV of unaffected controls (9.07 Ϯ 2.75 v 8.28 Ϯ 2.62 m/sec, P ϭ .005; Table 1 ). After adjustment for covariates, the AIx adjusted for a heart rate of 75 beats/min (AIx@75) was not significantly different in subjects with FCH compared to their unaffected relatives (21.6 Ϯ 12.7 v 15.6 Ϯ 14.1, P ϭ .96).
Cardiovascular Risk Factors and Pulse Wave Analysis as Predictors of the Presence of Cardiovascular Disease
Crude univariate odds ratio (OR) for the optimal cutoff values of clinical and biochemical variables and pulse wave analysis to predict past or present CVD are indicated in Table 2 . Age was the best predictor of CVD, with an age more than 53 years being equivalent to a 15.7 [6.9 -35.6]-fold increased risk of CVD. Of the modifiable clinical and biochemical risk factors included in traditional CVD risk factor screening, TC, waist circumference, and apoB best predicted CVD (OR for optimal cutoff points, respectively, 6.4 [3.1-13.2], 3.7 [1.9 -7.4], and 3.4 [1.7-6.5]). Compared to these separate clinical and biochemical risk factors, PWV was a better predictor of CVD: a value more than the cutoff point of 8.85 m/sec was equivalent to a 7.2 [3.3-15.5]-fold increased risk of CVD. In agreement with this, the area under the curve (AUC; as a measure of predictive ability) in receiver operating curve (ROC) analysis was larger for PWV (77%) than it was for TC (AUC 70%), waist (AUC 68%), or ApoB (AUC 62%; Table 2 ). The predictive ability of PWV for the presence of CVD extended beyond simple BP measurements, as the AUC for PWV (77%) was significantly higher than AUCs for MAP (60%), systolic BP (62%), and diastolic BP (56%) (all P Ͻ .01).
Next, we aimed to compare the CVD risk prediction ability of PWV and AIx measurements relative to the CVD risk prediction based on traditional risk factor screening. Because traditional risk factor screening includes multiple risk factors instead of separate risk factors, and also takes into account the modifier effect of "age" on all these risk factors, we compared the predictive ability of age-and gender-adjusted PWV and AIX with the most predictive combination of age-and gender-adjusted clinical and biochemical risk factors. Multivariate logistic regression analysis revealed that, of the age-and gender-adjusted traditional risk factors, a combination of TC, HDL-cholesterol, and systolic BP best predicted the presence of CVD in our population, with a R 2 of 33%. Fig. 1 shows that the combined predictive ability of these risk factors for the presence of CVD was comparable to the predictive ability of PWV: the area under the ROC curve was 0. By logistic regression analysis, the probability of classification affected CVD based on the optimal cutoff point for the combined clinical and biochemical risk factors was assessed at 37%. This is about equal to the 36% probability for the optimal cutoff point of age-and gender-adjusted PWV to predict CVD. In line with this, sensitivity and specificity for the prediction of CVD are of the same magnitude for PWV and for the combined clinical and biochemical risk factors (sensitivity, respectively, 81% and 78%; specificity 79% and 86%). However, for ageand gender-adjusted Aix@75, the probability of classification affected CVD based on the optimal cutoff point was only 24%, and sensitivity (70%) and specificity (69%) for the prediction of CVD were lower than for PWV and the combined clinical and biochemical risk factors.
Although the predictive ability of PWV for the presence of CVD was comparable to the predictive ability of the combined clinical and biochemical risk factors (TC, HDL-cholesterol, and systolic BP), addition of PWV to the AIx@75 ϭ augmentation index normalized for a heart rate of 75 beats/min; ApoB ϭ apolipoprotein B; BMI ϭ body mass index; DBP ϭ diastolic blood pressure; HDL-c ϭ high-density lipoprotein cholesterol; HOMA ϭ homeostasis model assessment; HR ϭ heart rate; hsCRP ϭ high-sensitive C-reactive protein; LDL-c ϭ low-density lipoprotein cholesterol; NS ϭ not significant; oxLDL/apoB ratio ϭ ratio of oxidized low-density lipoprotein to apoB; PWV ϭ pulse wave velocity; SBP ϭ systolic blood pressure; TC ϭ total cholesterol; TG ϭ triglycerides; VLDL-c/TG ratio ϭ ratio of very low-density lipoprotein cholesterol/ TG; WHR ϭ waist-to-hip ratio. Data are presented as mean Ϯ SD. Statistical comparisons between FCH patients and unaffected family members were made by the 2 test for dichotomous variables, and for continuous variables by general linear model (GLM) with age, gender (all variables), MAP, vasoactive medication use (AIx and PWV), and body height (AIx) as covariates and family number (all variables) as a random factor. * Unaffected relatives: ACE inhibitors (n ϭ 10), angiotensin II inhibitors (n ϭ 2), diuretics (n ϭ 9), ␤-blockers (n ϭ 13), and calcium antagonists (n ϭ 7). FCH patients: ACE inhibitors (n ϭ 11), angiotensin II inhibitors (n ϭ 9), diuretics (n ϭ 13), ␤-blockers (n ϭ 15), calcium antagonists (n ϭ 8), and nitrates (n ϭ 3). multivariable prognostic model, including these age-and gender-adjusted traditional risk factors, did not increase the predictive ability for CVD (AUC 0.84 [0.79 -0.89]).
Discussion
In the present study we found that arterial wall stiffness, as reflected by PWV, was increased in subjects with FCH as compared to their unaffected relatives. In addition, in patients with FCH and their unaffected relatives, PWV was a good predictor of the presence of CVD, although PWV had no additional predictive value when added to traditional risk factor screening.
Although previous studies have reported an increased arterial stiffness in patients with familial hypercholesterolemia (FH), 26 this is the first study to show that in FCH vascular wall stiffness is also markedly increased, despite the fact that mean plasma total cholesterol levels are considerably lower than in FH. Even when age, gender, MAP, and the use of vasoactive medication were taken into account, patients with FCH had a significantly increased PWV compared to their unaffected relatives. This was not the case for Aix. No significant difference could be demonstrated in AIx between FCH patients and their unaffected relatives. The larger difference in PWV between the two groups may be explained by the different vascular beds represented by these parameters. Whereas PWV represents the arterial stiffness of large conduit arteries, AIx is a marker of arterial wave reflection, which is dependent on the vascular resistance of small resistance vessels, 27 on PWV, and on the distance of the reflection point to the heart. As in all other major cohorts, "age" was the best univariate predictor of CVD. Considering the modifiable clinical and biochemical risk factors, waist circumference, systolic BP, and plasma concentrations of TC, apoB, and LDL-cholesterol were the best predictors of CVD in univariate analysis, whereas only TC and systolic BP, together with HDL-cholesterol, remained independent predictors of CVD in the multivariate model with adjustment for age and gender. Although unadjusted plasma concentrations of
FIG. 1.
Receiver operating curves of PWV, Aix, and a combination of clinical and biochemical risk factors to predict the presence of CVD in a cohort of 330 subjects from FCH families. TC ϭ total cholesterol; HDL ϭ high-density lipoprotein cholesterol; AIX@75, augmentation index normalized for a heart rate of 75 beats/min; PWV ϭ pulse wave velocity. hsCRP and oxLDL have been shown to predict CVD in healthy subjects, 28, 29 the predictive ability of both parameters in the current FCH population was minor compared to the traditional biochemical and clinical risk factors and also compared to AIx and PWV.
Most interestingly, age-and gender-adjusted PWV was as predictive for the presence of CVD as the most predictive combination of independent age-and gender-adjusted clinical and biochemical risk factors (TC, HDL-cholesterol, and systolic BP): Sensitivity for the prediction of CVD was comparable for PWV and for the combination of clinical and biochemical risk factors, whereas specificity was slightly lower for PWV. Recently, Willum-Hansen et al 14 showed that PWV was a significant predictor of future cardiovascular complications, above and beyond other risk factors in a large, population-based group of middle-aged subjects. However, in their study they excluded individuals with a previous history of MI and stroke. In the present study we show that, even in a population with an increased prevalence of CVD and the presence of multiple cardiovascular risk factors, PWV is a good predictor of the presence of CVD, although we could not demonstrate that PWV predicts the presence of CVD "above and beyond" the traditional risk factors in our high risk FCH population.
The predictive ability of AIx in our population was considerably lower than the predictive abilities of both PWV and the combined clinical and biochemical risk factors. The inferior sensitivity and specificity of AIx for the prediction of CVD may be explained by the fact that the relative importance of small vessel changes in the atherosclerotic process is larger in the early (subclinical) stages of the atherosclerotic process. Progression of advanced subclinical atherosclerosis to manifest clinical CVD is related to alterations in larger conduit vessels that are not represented by AIx.
With a sensitivity of 81% and a specificity of 79%, the cutoff value of 9.5 m/sec for age-and gender-adjusted PWV may be used as a reasonable screening tool to detect the presence of CVD in subjects from FCH families, although it should be noted that this cutoff value (and thereby sensitivity and specificity) may vary depending on the method used to measure the traveled distance of the pulse.
However, PWV had no contribution in the prediction of prevalent CVD in addition to conventional risk factor screening in our present study. This might be related to the relatively limited sample size or the cross-sectional design of our study. With larger sample sizes, derivation of ageand gender group-specific cutoff values may augment sensitivity and specificity of PWV as a screening instrument of CVD. Prospective studies have to be performed to investigate whether PWV is not only a good marker of the presence of CVD in FCH populations, but also of the development of CVD, and if so, whether the predictive ability of PWV adds to traditional risk factor screening. Not until the results of these prospective studies are available, the additive value of PWV measurements (or instead) of traditional risk factor screening remains questionable.
In conclusion, patients with FCH have an increased PWV compared to their unaffected relatives. In this crosssectional study, PWV predicts the presence of CVD equally well as any combination of clinical and traditional biochemical risk factors, but it has no additional value besides traditional risk factor screening. 26 
